BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 6, 2023
See today's BioWorld
Home
» Through Beigene, Amgen helps awaken the sleeping giant; $2.7B cash investment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Through Beigene, Amgen helps awaken the sleeping giant; $2.7B cash investment
Nov. 4, 2019
By
Lee Landenberger
and
Elise Mak
No Comments
When the time was right to make a powerful Western biotech welcome in China,
Beigene Ltd.
was ready when
Amgen Inc.
came calling. Its massive $2.7 billion cash equity investment in Beigene buys Amgen an oncology footprint in China.
BioWorld
Deals and M&A